Pharmacokinetics of dipyridamole in thalasemia
2
Issued Date
1989
Copyright Date
1989
Resource Type
Language
eng
File Type
application/pdf
No. of Pages/File Size
x, 103 leaves : ill.
Access Rights
open access
Rights
ผลงานนี้เป็นลิขสิทธิ์ของมหาวิทยาลัยมหิดล ขอสงวนไว้สำหรับเพื่อการศึกษาเท่านั้น ต้องอ้างอิงแหล่งที่มา ห้ามดัดแปลงเนื้อหา และห้ามนำไปใช้เพื่อการค้า
Rights Holder(s)
Mahidol University
Bibliographic Citation
Thesis (M.Sc. (Pharmacology))--Mahidol University, 1989
Suggested Citation
Benjamas Janchawee Pharmacokinetics of dipyridamole in thalasemia. Thesis (M.Sc. (Pharmacology))--Mahidol University, 1989. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/103207
Title
Pharmacokinetics of dipyridamole in thalasemia
Alternative Title(s)
เภสัชจลนศาสตร์ของยาไดพัยริดาโมลในคนไข้ธาลัสซีเมีย
Author(s)
Abstract
Dipyridamole had been used in alleviating number of clinical symptoms related to cardiovascular disorders. The presumed modulating activities of dipyridamole on platalet function suggest its therapeutic potential for hypoxemic syndrome commonly associated with splenectomized thalassemia patients. The pharanacokinetics data of dipyridamole for proper dosing regimens in thalassemia patients is essentially nonexisted. This study was designed to develop an dHPLC-method for monitoring dipyridamole in human blood: both in the plasma and the red blood cells, and study its pharmacokinetic nature in thalassemia so that an accurate dosage regimen could be develop for very unique group of individuals. Being a compound contains chromophore that produces both UV-(max.280 nm) and fluorescence (max.ex.285 & em.475 nm) spectra of which the molar absorptivity of the latter is very strong and thus its detecting sensitivity at 1 nanogram level had been satisfactory developed. Under the acidic chromatographic condition the silica-base C-18 column is less affected and is highly favorable over other conventional methods that the sample preparation in complex matrix, i.e. human blood can be accordingly simplified. The use of minimal amounts of Pic-B6 (2uM) is recommended in this study against the traditional use of ralatively high concentration of the pairing reagent (i.e.,5MM). This was found to have additional advantages in term of efficiency, reliability and sensitivity. The pharmacokinetics parameters of dipyridamole after a single oral dose of 50mg in 8 thalassemia (4 non-splenectomized & 4 splenctomized) and 4 normal volunteers were accordingly determined. It was found that thalassemia patients could absorb less dipyridamole than normal individuals judging from the smaller AUC in thalassemia. The deviated changes of the internal mileiu in the gastrointestinal tract in thalassemia was believed believed to be the contributing cause of delayed in lag time and Tmax of dipyridamole in blood while the absorption rate nor other related pharmacokinetic parameters were not changed. Dipyridamole seems to stay longer inthe RBC than the plasma as the t(1/2)(...) was longer in the RBC, the site of its therapeutic artion. It was proposed that dosage regimen of dipyridamole could be better derived from the pharmacokinetic data of the RBC rather than the parameters commonly taken from the plasma. This would provide a more acurate monitoring adn better use of dipyridamole in thalassemia.
Description
Pharmacology (Mahidol University 1989)
Degree Name
Master of Science
Degree Level
Master's degree
Degree Department
Faculty of Science
Degree Discipline
Pharmacology
Degree Grantor(s)
Mahidol University